HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. (OTC:IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company’s Abbreviated New Drug Applications (ANDA) for generic versions of Urecholine® Tablets (Bethanechol Chloride Tablets USP) 5 mg, 10 mg, 25 mg, and 50 mg. Odyssey Pharmaceuticals, Inc. markets Urecholine for the treatment of acute post-operative and post partum non-obstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. Sales of both the branded and generic versions of Urecholine Tablets were approximately $33 million in the 12 months ended August 31, 2006, according to Wolters Kluwer Health.
